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1. Introduction 
Adverse reactions to food are currently classified into toxic and non-toxic reactions. There is 
a normal range of concentrations of naturally occurring toxic compounds, which can easily 
increase during food processing. For example, thermal processing can cause the unintended 
and undesirable formation of toxic compounds, such as acrylamide in fried potato chips and 
furan in sterilized canned vegetables, together with losses of certain nutrients. The incidence 
of non-toxic reactions depends on individual susceptibility to a specific food or food 
ingredient, although these reactions are often dose-dependent. The non-toxic types may be 
divided further into immune- and non immune-mediated reactions. The term 
“hypersensitivity” is used for immune-mediated reactions, and the term 'intolerance' is used 
for non immune-mediated reactions (Figure 1). Immune-mediated reactions may be IgE-
mediated (i.e., allergy or type I hypersensitivity) or non-IgE-mediated, whereas food 
intolerance may be enzymatic, pharmacologic or undefined. The incidence of immune-
mediated adverse reactions to foods has increased in recent decades. In healthy subjects, 
orally ingested dietary proteins induce antigen-specific systemic hyporesponsiveness, 
termed oral tolerance. This phenomenon is well described in animal models, although the 
mechanisms remain unknown. Abrogation of oral tolerance or failure to induce oral 
tolerance may result in the development of food hypersensitivity. Immune reactions that 
cause tissue damage may be mediated by four reaction types that were defined by Coombs 
and Gell [1] (Figure 2). Type I, or anaphylactic hypersensitivity, is mediated by the reaction 
of an antigen with specific IgE antibodies that are strongly bound through their Fc receptor 
(CD23, IgεR) to the surface of the mast cell. Crosslinking of Igε receptors by divalent hapten 
leads immediately to the release of mediators, for example, some cytokines [primarily 
interleukin 4 (IL4)] and histamine, which are both activities of eosinophil chemotactic factor 
(ECF) and neutrophil chemotactic factor (NCF) (Figure 2A). This type of hypersensitivity 
occurs within minutes of antigen exposure. Some reaction mediators produce local skin, 
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gastrointestinal and respiratory tract manifestations, and a systemic allergic reaction to an 
allergen that is associated with a dangerously low blood pressure. Moreover, some of the 
mediators exhibit chemoattractant activity and induce the infiltration of neutrophils, 
eosinophils, macrophages, lymphocytes and basophils within 6-12 h after challenge. The 
localized late-phase inflammatory response may also be mediated partly by cytokines that 
are released from mast cells. In type II or antibody-dependent cytotoxic hypersensitivity, 
antibodies recognize antigens on the surface of specific cells or tissues. Once activated, the 
complement system can initiate a variety of responses that can lyse and destroy cells. 
Phagocytic and cytotoxic K cells, which have receptors for the Fc-part of IgG or an activation 
component of complement, i.e., C3b, may also destroy cells (Figure 2B). In type III, or 
immune complex-mediated hypersensitivity, the soluble antigen can activate the 
complement and deposited phagocytes. Leucocytes may release tissue-damaging mediators 
and activate phagocytes, culminating in tissue damage. The complex can also induce 
thrombin-mediated platelet aggregation and release a vasoactive amine (Figure 2C). Type IV 
reaction, or delayed-type hypersensitivity, arises more than 24 h after an encounter with the 
antigen. Type IV reactions are mediated by antigen-sensitized CD4+ T cells (T helper cells) 
that release inflammatory mediators [e.g., IL2 and interferon-y (lFN-y)], attract phagocytes 
to site of infection, activate an inflammation response and lyse invading cells (Figure 2D). 
Because lytic enzymes are secreted from the phagocytic cells into the surrounding tissue, 
localized tissue destruction can progress. 
 
Figure 1.  
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Figure 2. Types of Allergy Mechanisms according to Coombs and Gell [1]. 
The mechanisms underlying of allergic sensitization to food include genetic susceptibility, 
aberrant barrier functions of the skin epithelium and gut mucosa and dysregulation of 
immune functions. Despite a wide range of clinical manifestations, there are at least two 
common prerequisites for the development of a general food allergy (FA). First, intraluminal 
antigens must penetrate the mucosal barrier of the intestine. Second, the absorbed antigens 
must cause harmful immune responses [2]. 
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2. Adverse reaction to milk 
Non-toxic adverse reactions to milk are primarily caused by either lactose intolerance or 
milk allergy. 
2.1. Lactose intolerance 
Milk intolerance is due to the inherited lack of the specific enzyme, β-galactosidase that is 
required to hydrolyze lactose. For lactose malabsorption, the most common therapeutic 
approach excludes lactose-containing milk from the diet. To make yogurt edible, exogenous 
β-galactosidases that hydrolyze yogurt lactose or probiotics for their bacterial lactase 
activity are added. However, further studies are required to clarify the role probiotics play 
in lactose intolerance therapy, which includes considering their well-known beneficial 
effects on intestinal function, gas metabolism and motility [3]. A prolonged contact time 
between β-galactosidase and lactose delays the gastrointestinal transit time and chronic 
lactose ingestion to improve colonic adaptation. It is known that high concentrations of β-
galactosidase are physiologically present in neonates, but a genetically programmed and 
irreversible decline of the activity occurs after weaning [4], which results in primary lactose 
malabsorption. The secondary hypolactasia because of intestinal mucosa brush border 
damage that increases the gastrointestinal transit time is a transient and reversible condition 
[5]. Bloating, flatulence, abdominal pain, the passage of loose and watery stools, excessive 
flatus and diarrhea are gastrointestinal symptoms of lactose intolerance [6]. However, 
lactose occurring in the colonic lumen does not necessarily produce gastrointestinal 
symptoms because of the variable amount of residual intestinal mucosal lactase activity that 
possibly digests lactose. The availability of recombinant β-galactosidase as an exogenous 
lactase has resolved problems concerning bacteria that release β-galactosidase during gastric 
passage. By this means, lactose is partially or fully degraded to glucose and galactose and is 
therefore easily eliminated by simple dietary adjustments that mediate the effects of lactose 
intolerance [7]. An accurate diagnosis of lactose intolerance can significantly reduce patient 
anxiety and avoid unnecessary examinations and treatments [8]. 
2.2. Milk allergy 
Cow's milk allergy (CMA) is a complex disorder that implies an immunologically mediated 
hypersensitivity reaction with varying mechanisms and clinical presentations. The type I 
reactions appear to be the most common immune reaction to milk. However, the dominance 
of IgE reactions (Type I) may be an artifact as the reaction is easy to diagnose because of an 
immediate IgE measurement, whereas other reaction types are more difficult to diagnose. 
Non-IgE-mediated hypersensitivity has been increasingly diagnosed, and it is likely that 
several mechanisms operate in an individual patient. In clinical work, hypersensitivities are 
classified as IgE- and non-IgE-mediated or as immediate and late reactions based on the 
appearance of the first types of symptoms [9]. Cow’s milk is a member of the “Big-8” food 
allergens that include egg, soy, wheat, peanuts, tree nuts, fish and shellfish in terms of 
prevalence [9]. The incidence of CMA varies with age. CMA is prevalent in early childhood 
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with reported incidences between 2 and 6% [10-12] and decreases into adulthood to an 
incidence of 0.1–0.5% [13-14]. It has been suggested that infants have milk allergies because 
milk is usually the first source of foreign antigens that they ingest in large quantities, and 
the infant intestinal system is insufficiently developed to digest and immunologically react 
to milk proteins. When milk is eliminated, the inflammation response is controlled. After 
several years, oral tolerance is developed, and milk can again be tolerated [15]. Most milk-
allergic children are considered symptom-free by 3 years of age, but several studies have 
indicated that older children may also have immune reactions to milk. Children whose 
CMA has been diagnosed at an age older than 3 years do not tend to outgrow the problem. 
In adults, CMA is less common than lactose intolerance [16-17], even though it has been 
reported that approximately 1% of the adult population has milk-specific IgE antibodies. 
However, studies on CMA in adults are scarce. Little is known about the clinical symptoms, 
eliciting doses, and allergens involved. It has established that CMA in adults is rare but 
serious [18]. In a study by Stöger et al. [19], the main target organs in adult CMA were the 
skin and the respiratory tract. Gastrointestinal (mild to moderate) and cardiovascular 
(severe) symptoms were observed less often in adults compared with children. Milk 
allergies and hypersensitivity may be more common now than they were several decades 
ago. Further, the prevalence of atopic diseases has also increased in recent decades. Because 
genetic diversity has not changed over a short period, environmental factors are believed to 
have influenced the phenotype. Such factors may include increased air pollution, such as 
passive smoking, and dietary factors, such as the duration of breastfeeding, amount of 
antioxidants and the type of dietary fats (favoring saturated fat and n-6 fatty acids). Another 
approach is the hygiene hypothesis, which states that early exposure to microbial antigens 
may reduce the risk of having allergies [20]. For as long as milk allergy and hypersensitivity 
have been experienced, and still may be, these conditions may be misdiagnosed as a disease 
other than an allergy/hypersensitivity, particularly if symptoms are delayed. Classical IgE-
mediated milk allergies with objectively recorded skin reactions may have been diagnosed 
easily, whereas hypersensitivity with subjective gastrointestinal reactions may have been 
diagnosed as lactose intolerance, irritable bowel syndrome or some other intestinal disorder. 
In adults, viral infection, antibiotic treatment or stress may alter intestinal integrity so that 
its balance is disturbed and the number of protecting agents, such as microflora and 
mucosal immunity, are altered [21]. This process may result in milk hypersensitivity. Over 
one-third of women with IgE-mediated reactions to milk proteins have been reported to 
exhibit their first symptoms of hypersensitivity during or shortly after pregnancy, and one-
quarter reported the first symptoms during a period of severe emotional stress [22]. 
3. Milk allergens 
No single major allergen has been identified in cow’s milk according to either challenge tests 
or laboratory procedures; [23]. Indeed, clinical challenge tests demonstrate that most CMA 
patients react to several protein fractions of cow’s milk and each allergenic protein may 
have several epitopes, which are widely spread along the molecules. The cow milk proteins 
prevalently implicated in allergic responses in children are the whey proteins α-
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Lactalbumin (α-La)(Bos d 4) and β-Lactoglobulin (β-Lg) (Bos d 5), in addition to the casein 
(CN) fraction (Bos d 8) [24-26]. In adults, the predominant allergen is CN, whereas 
sensitization to whey proteins is rare. Biochemical characteristic of allergenic cow milk 
proteins are reported in Table 1. Currently, milk allergen analyses are generally based on 
immunoassay methods, such as enzyme-linked immunosorbent assay (ELISA) [27]. 
Commercial test kits are available for the determination of CN, β-Lg, or total milk proteins 
(CN and β-Lg) [28]. Interlaboratory studies were performed to evaluate the reliability and 
reproducibility of these kits [29]. Antibody cross-reactivity has been reported for some milk 
proteins [30]. Confirmatory tests are required to corroborate ELISA detection results and 
improve the detection specificity of undeclared milk allergens. For the last several decades, 
mass spectrometry has become the dominant technology for the identification of peptides and 
proteins. The primary current approaches used for protein identification are top-down [31-33] 
and bottom-up [34] sequencing. Top-down sequencing involves introducing the intact protein 
into the gas phase. The protein is identified by measuring either the protein molecular weight 
or its fragmentation pattern using various techniques [35]. The bottom-up approach is more 
common. The sample is usually digested with an enzyme, such as trypsin, followed by 
accurate sequence analysis by tandem mass spectrometry (MS/MS) of the proteolytic 
fragments. For protein identification, an algorithm is used for database searching based on 
amino acid sequence assignments.  
 
Table 1. Chemical characteristics of cow’s milk proteins and their inclusion in the official list of 
allergens 
3.1. Casein 
The CN fraction is composed of four proteins  αs1-,  αs2-, β-, and κ-CN, in approximate 
proportions of 40%, 10%, 40%, and 10%, respectively, and αs1-CN is a major allergen 
according to IgE and T cell recognition data [36-39]. The specificity of the IgE response to the 
different purified CNs has been analyzed on 58 sera from patients allergic to whole-CN [40]. 
Cow’s Milk 
Proteins (100% )
 Protein
Allergen 
Name
Allergenicity
Total 
Protein %
MW 
(kDa)
pI
Amino Acid 
Residues
Calcium 
sensitivity
Phosphate 
groups
Caseins (80%) αs1-Casein Bos d 8  Major 32 26.6 4.9 - 5.0 199 +++ 8-9
αs2-Casein " " 10 25.2 5.2 - 5.4 207 ++++ 10-13
β-Casein " " 28 24,0 5.1 - 5.4 ++ 4-5
γ1-Casein " " Traces 20,5 5.5 181 + 1
γ2-Casein " " Traces 11,9 6.4 104
γ3-Casein " " Traces 11.5 5.8 102
κ-Casein " " 10 19 5.4 - 5.6 169
Whey proteins 
(20%)
α-Lactalbumin Bos d 4  Major 5 14.2 4.8 123
β-Lactoglobulin Bos d 5  Major 10 18.3 5.3 162
Immunoglobulins Bos d 7 – 3 150 – – – 1-3
BSA Bos d 6 – 1 66.3 4.9 - 5.1 582
Lactoferrin – – Traces 80 8.7 703
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Multi-sensitization was observed, which most likely corresponded to a co-sensitization to 
the different CN components after the disruption of the CN micelles. The CN fractions 
cross-link to aggregates termed nanoclusters, which combine into micelles. In the new state 
of aggregation, there is a hydrophobic central part and peripheral hydrophilic one that 
include phosphorylation sites. Although the primary structure of CNs is known, the micelle 
structure remains relatively unknown. αs2-, αs1-, and β-CN bind calcium to form a core that 
is covered with a κ-CN layer. The κ-CN latter protects CN micelles from precipitation in the 
presence of milk constitutive calcium ions. During the last five decades, different models for 
the structure of the bovine CN micelle have been proposed. Walstra has summarized the 
common structural elements into a “ball-shaped model” [41]. According to Walstra, a well-
accepted model considers the CN micelle as follows: (i) it is roughly spherical; although it 
does not have a smooth surface; (ii) it is built of smaller units, termed sub-micelles, which 
mainly contain CN and have a mixed composition; (iii) sub-micelles vary in composition 
and consist of two main types-one primarily consists of αs and β-CNs and the other 
primarily consists of αs- and κ-CNs; (iv) the sub-micelles can be linked together by small 
calcium phosphate clusters bridging them; (v) the sub-micelles aggregate until they have 
formed a micelle in which those with κ-CN are outside; and (vi) consequently, molecular 
chains of the C-terminal end of κ-CN protrude from the micelle surface to form a “hairy” 
layer that prevents any further aggregation of sub-micelles by steric and electrostatic 
repulsion. The hairy layer is also held responsible for the stability of the micelles against 
flocculation. Destabilization of CN micelles can be made by treating milk with milk clotting 
enzymes, which limitedly degrade κ-CN affording to CN micelle fusion and formation of a 
para-κ-CN aggregate. Finally, a variable proportion, up to 5% total, consists of a 
heterogeneous group of CNs termed γ-CNs (γ-CN) that result from the limited proteolysis 
of β-CN by plasmin, the native milk protease. Plasmin disperses in low amounts from blood 
to milk during secretion to generate CN fragments whose structure are shown in Figure 7 
with peptides labeled according to the current nomenclature [42]. CNs are highly sensitive 
to proteolysis and do not maintain a unique folded conformation [43], which has led them to 
being termed rheomorphic. Because the folded structure is limited, heating does not 
generally change the structure and hence its IgE binding [44]. αs1-CN, αs2-CN, and β-CN can 
chelate Ca2+, Zn2+, and Fe3+, respectively. The four CNs share little sequential homology, but, 
despite this lack of homology, simultaneous sensitization is often observed.  
3.1.1. αs1-CN 
αs1-CN consists of major and minor polypeptides that include the same amino acid sequence 
but have different degrees of phosphorylation [45]. Allergenic epitopes were identified by 
Spuergin et al. [46] in αs1-CN regions 19–30, 93–98 and 141–150 as immunodominant 
epitopes. Some sequential IgE-binding regions were recognized at AA 17–36, 39–48, 69–78, 
93–102, 109–120, 123–132, 139–154,159–174, and 173–194 using sera from nine older children 
(> 9 years old), and the epitopes AA 69–78 and 175–192 were recognized by 60% and 80% of 
sera, respectively, from older children [47]. A later study by Elsayed et al. [48] has 
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demonstrated that the N- and C-terminal peptides, AA 16–35 and 136–155, respectively, 
have the highest human IgE-binding affinity, and AA 1–18 and 181–199 exhibited high 
binding to rabbit IgG. cDNA coding for αs1-CN from a bovine mammary gland cDNA 
library with allergic patients’ IgE Abs has been isolated. IgE epitopes of αs1-CN were 
determined with recombinant fragments and synthetic peptides that spanned the αs1-CN 
sequence using microarray components and sera from 66 cow’s milk-sensitized patients. 
The allergenic activity of recombinant αs1-CN and the αs1-CN-derived peptides exhibited IgE 
reactivity, but mainly the intact recombinant αs1-CN induced strong basophil degranulation. 
The results indicate that αs1-CN contains several sequential IgE epitopes, but the isolated 
peptides were less potent than the complete allergen in initiating effector cell degranulation. 
These results suggest that primarily intact αs1-CN or larger IgE-reactive portions thereof are 
responsible for IgE-mediated symptoms of FA [49]. 
3.1.2. αs2-CN 
αs2-CN is the most hydrophilic of the four CNs because of an anionic group cluster. αs2-CN 
consists of two major and several minor components that exhibit varying levels of 
phosphorylation. αs2-CN contains two cysteines and forms disulfide-linked dimers. Using 99 
synthetic decapeptides, 10 regions binding IgE from the sera were identified as allergenic, 
i.e., 31–44, 43–56, 83–100, 93–108, 105–114, 117–128, 143–158, 157–172, 165–188, and 191–200 
[50]. Studies on the presence of αs2-CN epitopes 87–96 and 159–168 with weak binding to 
145–154 and 171–180 with originate from individuals with persistent cow’s milk allergy. 
Patients with transient allergies exhibited only weak binding to αs2-CN peptides [51]. 
3.1.3. -CN 
β-CN is the most hydrophobic component of total CN. Sequence variants are known 
because of both partial proteolysis and variant genes [42]. β-CN is less phosphorylated than 
αs1-CN and αs2-CN, with five potential phosphorylated sites located in the N-terminal 
region. Plasmin cleaves β-CN into γ1-, γ2-, and γ3-CN. Synthetic decapeptides were used to 
estimate the β-CN region that binds IgE of patients, and peptides 1–16, 45–54, 55–70, 83–92, 
107–120, 135–144, 149–164, 167–184, and 185–208 were described as typical for patients with 
persistent CMA. Sera from eight young patients exhibited a simpler IgE pattern because the 
sera were bound to peptides 1–16, 45–54, 83–92, 107–120, and 135–144 with weak binding to 
residues 57-66 and the C-terminal region [52]. 
3.1.4. κ-CN 
κ-CN consists of a major carbonate-free component and a mini-bonded polymer that ranges 
from dimers to octamers. κ-CN plays an important role in the stability and coagulation 
properties of milk [89]. κ-CN is most likely more structured than αs- and β-CN and contains 
specific disulfide bonds [53-54]. The β-CN can rearrange on heating [55]. κ-CN is sensitive to 
proteolysis and is hydrolyzed by chymosin to produce para-κ-CN and caseinomacropeptide 
in the cheese-making process. Allergenic potential sequences remain in cooked cheeses. κ-
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CN is essential to the stability of CN micelles [55]. Diagnosing patients with persistent cow’s 
milk allergies with the use of 80 overlapping synthetic decapeptides helped to identify some 
regions that bind to IgE from sera, specifically sequences 15–24, 37–46, 55–80, 83–92, and 
105–116 [37]. 
3.2. Whey proteins 
Whey proteins contain two major allergens, β-Lg and α-La, and minor constituents, e.g., 
lactoferrin, bovine serum albumin (BSA), and immunoglobulins. In this fraction, proteolytic 
fragments of CN and fat globule membrane proteins can occur. 
3.2.1. β-Lg 
β-Lg (Bos d 5) is the major whey protein in ruminant milks, comprising 50% of the total 
whey protein. β-Lg is found in the milk of other mammals but is missing from the milk from 
rodents, lagomorphs and humans. Notably, 13-76% of patients are found to react with β-Lg. 
β-Lg has a molecular weight of approximately 18 kDa [37] and belongs to the lipocalin 
superfamily. The β-Lg (Bos d 5) allergen is capable of binding lipids, including retinol, β-
carotene, saturated and unsaturated fatty acids, and aliphatic hydrocarbons, and 
transporting hydrophobic molecules, which is an important function [56-57]. Under 
physiological conditions, β-Lg is an equilibrium mixture of monomeric and dimeric forms. 
The proportion of monomers increases after heating to 70°C. β-Lg contains five cysteine 
residues, of which four are engaged in intra-chain disulfide bridges. Because of the single 
unpaired cysteine, β-Lg predominantly exists as a stable dimer that tends to dissociate into 
monomers at a pH between 2 and 3 [58]. β-Lg is present in several variants, i.e., A, B, and C, 
that are found in the Jersey breed. β-Lg is sensitive to thermal processes. Ehn et al. [59] 
reported that heating β-Lg to 74°C and 90°C reduced IgE binding significantly. Heating to 
90 °C reduced IgE binding more extensively. Chen et al. [60] reported that nearly 90% loss 
and denaturation of β-Lg are observed in processed milk and that high heat is the major 
cause of protein aggregation. Circular dichroism demonstrated no significant conformational 
changes at temperatures below 70°C for as long as 480 s. The rapid changes of β-Lg occurred 
between 80°C and 95°C. Fifty percent of the maximal changes could be reached within 15 s. 
Guyomarc’h et al. [61] reported that large micellar aggregates, 4 × 106 Da, are formed upon 
heating milk that contained 3:1 ratios of β-Lg and α-La together with κ-CN and αs2-CN. 
Proteolysis and use of monoclonal antibodies proved that β-Lg possesses many allergenic 
epitopes spread over the β-Lg structure [62]. Major human IgE epitopes for β-Lg amino acid 
fragments are composed of residues 41–60, 102–124, and 149–162; intermediate 1–8, 25–40, and 
92–100; and minor 9–14, 84–91, 125–135, and 78–83 [63]. Similar IgE epitope regions (21–40, 40–
60, 107–117, and 148–168) were reported for a rat model of β-Lg allergy [64,65]. 
3.2.2. α-La 
α-La (Bos d 4) is a homologue of C-type lysozymes. It is a member of glycohydrolyase 
family 22 and Pfam family and weighs 14,186 Da in the mature form and between 15,840 to 
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16,690 Da for the glycosylated forms. α-La is stabilized by binding to calcium. Polverino de 
Laureto et al. [66] reported that α-La is cleaved by pepsin at pH 2 in the region of residues 
34–57, which produces large fragments. Veprintsev et al. [67] reported that differential 
scanning calorimetry of α-La at pH 8.1 exhibited transitions at 20°C–30°C with calcium 
chelator ethylene glycol tetra-acetic acid and near 70°C with the addition of calcium. 
McGuffey et al. [68] investigated the heating effects of purified α-La and demonstrated that 
the extent of irreversible aggregation varies at temperatures between 67°C and 95°C. When 
milk is heated to 95°C, α-La denatures more slowly than β-Lg. The folded α-La structure is 
destabilized at low pHs with the formation of a molten globule[69]. The stability to 
denaturation is also strongly lowered by the reduction of disulfides [70]. Disulfide exchange 
can occur during thermal denaturation, which leads to the formation of aggregates [71]. 
Although evolved from a lysozyme [72], the function of α-La is to form a complex with 
galactosyltransferase, which alters the substrate specificity and increase the lactose synthase 
rate in milk. The galactosyltransferase and α-La is termed lactose synthase [73]. α-La alone 
does not have any catalytic activity as a lysozyme or a synthase. Several other properties of 
α-La and possible additional functions have been described [74], which include binding of 
several ligands and antimicrobial activity, both as a complete molecule [75] or as peptides 
[76]. The cytotoxic effects against mammalian cells have also been investigated [77]. The 
major component of α-La is unglycosylated. However, a mass spectrum of α-La contains at 
least 15 distinct peaks [78], and a minor glycosylated form (approximately 10%) results from 
asparagine 45 glycosylation. A study concerning the allergenic properties of α-La 
demonstrated that in 60% of the study patients, allergic sera were specific for intact α-La 
with only 40% binding to peptides obtained after tryptic hydrolysis. Residue 17–58 was the 
most frequently recognized in the sequence 59–93, 99–108, and 109–123 [79]. The linear 
epitopes were identified by using sera of patients suffering from persistent allergies and IgE 
to cow’s milk levels > 100 kU(A)/L. Serum IgE bound most strongly to peptides 1–16, 13–26, 
47–58, and 93–102 [80]. 
3.2.3. Minor allergens 
Bovine serum albumin (BSA) (Bos d 6), which is a heat-labile protein, is a major allergen in 
beef but a minor allergen in milk [81-84]. Accordingly, beef allergic individuals are at risk of 
being allergic to cow's milk and vice versa. BSA allergies account for 0-88% of sensitization 
events, whereas clinical symptoms occur in up to 20% of patients. BSA is one of the proteins 
most frequently involved in binding with circulating IgE [85-86]. Bovine immunoglobulins 
(Bos d 7) may be also responsible for clinical symptoms in CMA. 
4. Post-translational modifications 
In evaluating the allergenic potential of a protein, post-translational modifications of amino 
acid residues should be considered in addition to sequential and conformational IgE 
binding domains. Notably, such modifications may either generate additional IgE epitopes 
or induce changes in protein folding that affect IgE-protein interactions. Accordingly, 
recombinant allergens do not generally have the IgE-binding capacity of their natural 
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counterparts, most likely because of a deficiency in the post-translational events [87]. 
Regarding milk proteins, selective phosphorylation of serine residues in all of the four CNs, 
O-glycosylation of threonine residues in κ-CN and N-glycosylation of asparagine residues 
in α-La have been long described. 
4.1. Phosphorylation 
The removal of phosphate groups from CNs significantly reduces the CN-binding capacity 
of IgE from patients who suffer from milk allergies, which indicates that at least part of anti-
CN IgE is directed against CN domains that comprise a major phosphorylation site [88, 89]. 
It has been suggested that currently observed co- and cross-sensitization to the different 
CNs that are encoded by different genes and display few amino acid sequence homologies 
can be caused by the occurrence of common highly conserved major sites of 
phosphorylation, i.e., the Ca2+ binding CN sequence SerP-SerP-SerP-Glu-Glu that 
corresponds to αs1-CN 66-70, β-CN 17-21 and αs2-CN 8-12 and 56-60 [87]. Most likely, 
sensitization to milk is caused by a large release of phosphopeptides that are resistant to 
further degradation by digestive enzymes [90] during intestinal proteolysis of milk proteins. 
However, serine phosphorylation poorly affects the overall antigenic potential of individual 
CNs. Notably, antisera raised against native β- and αs2-CNs can recognize their targets after 
dephosphorylation or deletion of a major phosphorylation site [87]. Furthermore, polyclonal 
antisera that are produced in rabbits using a bovine β-CN 1-28 phosphorylated peptide as 
an antigen have been utilized to detect all of the tryptic phosphopeptides that originate 
exclusively from the 1-28 region of β-CN, regardless of the content of the phosphorylated 
Ser residues, and none of those generated by the other bovine CN fractions [91]. β-CN from 
human milk contains the phosphopeptide cluster 5Glu-Ser-Leu-SerP-SerP-SerP-Glu-Glu12, 
also found in the bovine β-CN sequence 14-21; however, a lower level of phosphorylation 
has been generally observed. For example, according to the phosphopeptide analysis of 
human milk that is reported in Table 2 and Figure 3, the 2092.8 Da component, which 
corresponds to β-CN(f2-18)2P, caused the third peak in intensity order in combination with 
the fully phosphorylated components. This lower phosphorylation level is lacking in its 
bovine counterpart. The overall higher degree of phosphorylation of bovine CNs can play a 
role in sensitizing humans to bovine milk. 
4.2. Glycosylation 
The effect of glycosylation on the allergenic potential of milk proteins has been long 
disregarded despite efforts to identify the domains responsible for the allergenicity of milk 
proteins, mostly based on an epitope mapping approach. Notably, the role of carbohydrate 
epitopes in initiating an allergic reaction is still unclear [92]. Potential glycosylation sites 
have been identified in major milk proteins, i.e., N45 and N71 of mature α-La [93] and T131, 
T133, T135, T136, T142, and S141 of mature κ-CN [94]. Approximately 10% of α-La has been found 
glycosylated at N45, giving rise to at least 14 distinct peaks by electrospray-ionization mass 
spectrometry analysis [95]. However, these glycosylated forms were not included among the 
IgE epitopes in a study because they were not detected by matrix-assisted laser 
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desorption/ionization time-of-flight (MALDI-TOF) analysis of α-La; notwithstanding in the 
same study, IgE reactivity of sera from patients allergic to α-La were proven to be sensitive 
to periodic acid treatment [93]. As reported in Table 3, the genetic variant A of water buffalo 
α-La that carries an N45→D45 substitution cannot be glycosylated. To assess the effect of 
glycosylation on the allergenicity of α-La, it might be used as substrate for IgE reactivity 
testing of sera from patients sensitized to α-La. 
 
Table 2. Identification of human milk soluble TCA 12% peptide fractions enriched on hydroxyapatite 
after MALDI-TOF analysis by FindPept (http://www.expasy.org/tools/findpept.html) software. 
Despite some indications that the allergenic character has been identified in the glycosidic 
moiety of native κ-CN [96], at present this issue remains to be settled. Glycated forms of κ-
CN account for approximately 40% of the κ-CN that normally occurs in bovine milk, but 
glycans are not randomly distributed among potential glycosylation sites. The hierarchy of 
glycan addition proceeds according to the order T131, T142, T133, whereas the other sites 
remain latent until these sites are occupied [97]. κ-CN is cleaved by chymosin during the 
primary stage of cheese making at the peptide bond F105-M106. The C-terminal 106-169 
fragment, known as glycopeptide because all of the glucides originally present in κ-CN are 
Theoretical Measured MH
+
2488.1 2489.1 β-CN (f1–18)5P
2408.1 2409.1 β-CN (f1–18)4P
2328.2 2329.1 β-CN (f1–18)3P
2248.2 2249.3 β-CN (f1–18)2P
2168.2 2169.2 β-CN (f1–18)1P
2252.0 2252.7 β-CN (f2–18)4P
2172.0 2173.0 β-CN (f2–18)3P
2092.0 2093.0 β-CN (f2–18)2P
2012.0 2013.0 β-CN (f2–18)1P
3100.8 3101.0 β-CN (f1–23)5P
3020.8 3021.8 β-CN (f1–23)4P
2940.9 2941.0 β-CN (f1–23)3P
2860.9 2861.9 β-CN (f1–23)2P
2780.9 2781.9 β-CN (1–23)1P
3077.0 3078.9 αs1-CN (f15–38)3P
3068.1 3069.1 αs1-CN (f12–36)2P
2488.5 2489.5 αs1-CN(f8–27)2P
2408.5 2409.5 αs1-CN (f8–27)2P
2118.8 2119.5 αs1-CN (f68–83)5P
Molecular mass (Da)
CPP identification
Human β-Casein
Human αs1-Casein
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retained, is released and lost in the whey. Therefore, cheese is devoid of any glycosylated 
major component. Potential allergenicity of κ-CN glycoforms has been suggested by 
analyzing the IgE binding capacity of an individual human serum from an adult atopic 
patient who had outgrown a cow milk allergy in early childhood. Bovine κ-CN has been 
selectively recognized by IgE immunostaining of an electrophoretic profile of milk proteins. 
No additional IgE-reactive proteins other than bovine κ-CN have been found in either 
bovine cheese, regardless of the cheese making technology and time ripening, or in ewe, 
goat and water buffalo milk. Moreover, chemical removal of glucide chains from bovine κ-
CN has not impaired IgE binding, thus proving a primary involvement of the glycoside 
moiety of the protein in IgE recognition. According to the specificity displayed by IgE, N-
acetylneuraminic acid as a terminal unit of a tetrasaccharide chain has been argued to be an 
IgE epitope [98]. 
 
Figure 3. Mass spectrum of human milk soluble TCA 12% fraction enriched on hydroxyapatite by 
MALDI-TOF. 
 
Table 3. Position and amino acid differences among the genetic variant of α-La from four animal 
species. 
Species
Bovine A Gln Gly Asn
Bovine B Arg Gly Asn
Water buffalo A Arg Asp Asp
Water buffalo B Arg Asp Asn
Caprine Gln Asp Asn
Ovine Gln Asp Asn
Site 10 17 45
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5. “Allergenomics”  
The application of proteomic methodologies for the analysis of food allergens has been 
termed “allergenomics” [99]. For “type I” FA, IgE-binding indicates that the target carries 
the risk to be an allergen. MS-based proteomic methods have identified many proteins and 
allergens. MALDI [100] and electrospray ionization (ESI) [101] and MS/MS sequencing are 
the techniques most widely used to produce high-quality spectra of post-translationally 
modified peptides [102-104] or intact proteins (see [105]). The characterization of 
glycosylated allergens has been partly overcome by specific enrichment using lectin or 
hydrophilic resins (HILIC) prior to MS analysis [106,107]. Native and de-glycosylated 
peptides are analyzed by MALDI or ESI-MS. Because of the difficulty of profiling 
oligosaccharides released by glycoprotein [108-110], glycan profiles are obtained after 
permethylation of the oligosaccharide chains according to the procedure of Das et al. [111]. 
By this means, glycosylated site(s) are identified together with the peptide backbone. 
Although widespread, several studies are dedicated to milk protein analysis for the 
detection of allergenic proteins or peptides in dairy products. Thus is determined by the 
concentration of allergenic compounds in food products that are often secondarily masked 
by dominant non-allergenic proteins. Among the various methods currently used to detect 
allergens in food products, immunochemical techniques that rely on antibody-binding 
properties have been developed. Commercially based kits are used for rapid screening, and 
enzyme-linked immunosorbent assays (ELISA) provide evaluations. Limits of detection 
(LOD) attained by ELISA tests are in the range of 1–5 ppm. Because the epitopes to be 
detected and their possible cross-reactivity with matrix components are unknown, detection 
reliability strongly depends on various factors that include the thermal changes of whey 
proteins, which are of primary importance. Furthermore, in several foods, linear epitopes 
can be released by parent protein hydrolysis, whereas retain their allergenic potential. As 
cited above, MS measurements can be finalized to evaluate the molecular mass of proteins 
and derived-peptides (MS1), determine the amino acid sequence and identify post-
translational modifications (MS/MS or MSn). Two-dimensional electrophoresis (2DE) 
separates proteins according to the pI (i.e., first dimension, isoelectric focusing, IEF) and 
subsequently molecular weight (SDS-PAGE) in an orthogonal dimension. By this means, the 
separation of thousands of proteins has been achieved using highly specific stains that 
visualize specific protein classes, i.e., phosphoproteins, or nonspecific stains that 
simultaneously target total proteins without particular functional groups. Protein spots are 
localized, excised from the gel and subjected to an in-gel tryptic digestion. Mass 
spectrometry analysis either by MALDI reflectron TOF or microcapillary liquid 
chromatography MS-MS detects the proteins based on the expected masses of peptides 
available in databases and other plant proteins in pollen diffusates. More directly, tandem 
mass spectrometry is used to identify the peptide sequence and search for allergens in 
databases. More elegantly, allergens are localized on the gels after a one- or two-
dimensional electrophoretic separation followed by a nitrocellulose transfer of the proteins 
(i.e., western blotting), which is stained with sera from allergic patients as a source of 
specific IgE. Combined with the analysis by mass spectrometry of electrophoretically 
separated allergens, immunoblotting is useful for the rapid determination of allergen 
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identities. Allergen–IgE complexes are also detected using conjugated anti-human IgE as a 
secondary antibody. Once localized in a 2DE map, the allergen can be monitored using 
allergen specific antibodies [112,113]. Immune-reactive allergenic protein(s) are identified 
along the immunoblots by comparison with a reference electrophoretic map. All of the 
major milk proteins are allergen candidates because sera of allergic patients contain various 
percentages of immune-reactive proteins that are recognized by IgE [114]. The order of milk 
protein allergenicity is as follows: αs2-CN>αs1-CN>β-CN>κ-CN>β-Lg> serum albumin > IgG-
heavy chain>Lf. This list contains allergenic proteins that have been identified by 
experiments on several MS platforms [115]. Thus far, it is quite difficult to find a separation 
method that can accommodate the diversity of proteins equally. Therefore, modern 
separation techniques have been performed off-line or by online ion-exchange/reversed 
phase liquid chromatography prior to MS analysis. ESI-MS is currently the interface most 
frequently used to perform an LC separation of intact proteins. The protein identification is 
most commonly achieved after a proteolytic digestion and molecular weight determination 
of the LC-separated peptides. “Shotgun” proteomics is the most effective LC/MS-based 
strategy because a trypsin-digested protein sample generates thousands of peptides that are 
subsequently separated by LC prior to MS/MS sequencing [103,116]. Proteins with at least 
one matching peptide are candidates to occur in the sample. However, with CNs, it is 
difficult to determine which fractions are present in the sample if they share the same set of 
phosphopeptides or have only one constituent peptide detected. LC-Q/TOF MS/MS has 
been used to detect wine CN as a fining agent. Two peptides were identified from αs1-CN 
and four peptides from the tryptic digestion of α- and β-CNs [117]. A similar strategy could 
be applied to monitoring allergens in processed milk products. Signature peptides could be 
identified as CN or whey protein allergens by submitting protein concentrates to 
trypsinolysis. In this manner, information on the molecular weight of the intact allergen is 
lost, but cross-reactive immunogenic peptides can be discriminated. Because of the higher 
sensitivity of MS in the detection of peptides, MS expands the dynamic range of the protein 
species detected. MS is a method for discovering “hidden” or traces of allergens. Proteomics 
has become pivotal to the development of modern structural immunology and to the 
understanding of interacting systems that are involved in immune responses, regardless of 
FA status. 
5.1. Allergen quantification methods 
Difference gel electrophoresis (DIGE) is utilized to compare multiple proteins in samples 
migrating in parallel in the same chamber. The proteins are labeled with three distinct 
fluorescent dyes on the same 2D gel and differentially visualized via fluorescence at 
different wavelengths. This methodology enables the detection of a differential presence of 
proteins and small differences in protein abundance. Allergens can be quantified by LC–MS. 
An accurate evaluation of the protein/peptide requires a suitable standard. In the direct 
quantification of intact proteins, the intensity of multi-charged analyte ions is compared 
with that of an internal or external standard. For example, quantification of cow’s milk 
allergens in fruit juice samples [118] and whey drink [119] was performed by 
simultaneously monitoring several multiple-charged ions of whey protein components. 
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With a similar approach, internal standard β-Lg was used to quantify non-bovine β-Lg in 
different milk-derived products [120]. The use of “bottom-up” methods, such as SILAC, 
ICAT, and iTRAQ, for quantitative analysis in proteomics has progressively increased 
[121,122]. Quantification of allergens in complex samples requires simple and precise 
methods of analysis, such as selected reaction monitoring (SRM) [123]. SRM is presently 
considered the gold standard for absolute quantification, whereas multiple reaction 
monitoring (MRM) can monitor the masses of selected signature peptides. For an allergen 
evaluation, internal reference peptides are required for food product monitoring by LC–
SRM MS [124]. Hydrolyzed protein samples are spiked with known amounts of synthetic 
peptides and monitored by LC–MS in the SRM mode. Absolute amounts of peptide(s) are 
determined by the ratio of the ion intensities of natural and synthetic peptides (Figure 4). 
 
Figure 4. Mass Spectrometry procedure analysis for protein absolute quantification. Proteotypic 
peptides are selected with a preliminary fullscan. For quantitative analysis whole protein extracts are 
trypsinized and the peptide mixture is spiked with external standard peptide. Proteotypic peptides 
(blue colored) selected as analytical probes of the target protein(s), are quantified by comparing the 
ionic intensities.  
This strategy has demonstrated its validity for using signature peptides as analytical 
surrogates to measure allergens in crude protein extracts. One advantage of the SRM 
procedure is the possibility of one-step monitoring of a variety of allergens. Recently LC–
triple quadrupole MS operating in an MRM mode has been effectively demonstrated to 
simultaneously detect allergens from seven different potentially allergenic matrices, such as 
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milk, eggs, soy, hazelnuts, peanuts, walnuts and almonds. The detection limits were in the 
10-1000 µg/g range. However, prior knowledge of allergens was required to monitor the 
most suitable allergenic peptides [125]. Based on the above-specified considerations, 
allergen evaluation requires the following: (i) allergen extraction from the food; (ii) enzyme 
proteolysis, usually trypsinolysis; and (iii) identification of signature peptides that are 
characteristic of food proteins or food ingredients. The signature peptides should be 
determined experimentally by prior LC/MS analysis of food-derived digested protein 
extracts.  
5.2. Standardization of allergen preparations 
Although the search for clinically relevant allergens has progressed, the characterization of 
allergens still requires studies on milk proteins as starting material. Pure native and 
recombinant allergens are needed as reference materials to calibrate methods among 
different laboratories. Recently, a panel of 46 food plant and animal allergens [126,127,128] 
has been made available within an EU-funded research project. In a recent 2DE application, 
calibration has been utilized for microbial complex protein systems using data obtained by 
MS [129]. Developing more allergen standards could be realized in the near future. 
Moreover, the search for allergenic sequence stretches would comprise only those immuno-
dominant produced during digestion that can to translocate the gut barrier and reach the 
mucosal immune system. Among the digestion/adsorption models of food protein stability, 
pepsin digestion has been included in the Food and Agriculture Organization/World Health 
Organization to assess food safety [130]. A model study has established milk-derived 
peptide candidate-mediated resistance to proteases to display allergic effects. The survival 
of milk protein epitopes [131,114] requires structure determination. To this end, a simulated 
digestion of bovine milk proteins in vitro that includes the sequential use of pepsin, 
pancreatic proteases, and extracts of human intestinal brush border membranes, has 
allowed the identification of produced peptides by MS. The presence of characteristic β-
Lg resistant peptides could implicate β-Lg in the case of a cow’s milk allergy [132]. The 
identification by MS of peptides arising from simulated digestion is complicated by a lack 
of enzyme specificity. Currently, there is no treatment to fully resolve or provide long-
term remission from FA allergies. The research for therapy is mainly focused on the 
introduction of anti-IgE antibodies and specific oral tolerance induction. Immunotherapy 
appears to be an attractive approach; however, the risk of anaphylaxis should be 
considered. To this purpose, engineered proteins have been designed, i.e., anaphylaxis-
initiating epitopes have been removed within these proteins, while preserving the 
tolerance-inducing epitopes [133-135]. It appears clear that to successfully pursue similar 
strategies, the precise identification of epitopes is necessary. It is expected that such 
approaches will be extended to an increasing number of food sources, whereby MS will 
play a key role for characterizing novel protein entities. The accurate characterization of 
the offending sequences could also be the starting point for developing less allergenic 
food products through the use of enzymatic, microbiological and technological processes 
to effectively remove allergens [136–139]. 
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6. Dairy research versus CMA 
6.1. Milk and dairy products from mammals different from cow 
According to the current clinical approach to FA and intolerance based on an elimination 
diet, the treatment of choice is complete avoidance of cow milk. Although of moderate 
importance in an adult diet, cow milk elimination has a significant nutritional significance in 
the infant diet, especially during early childhood. Milk from other mammals has been 
suggested as a possible alternative to cow milk. At first, goat milk had been proposed as a 
hypoallergenic infant food or cow milk substitute in human diet, but much of this thesi has 
no credible scientific evidence. Despite the immunological cross-reactivity between cow and 
goat milk proteins, due to the close biochemical similarity associated with the same 
phylogenetic origin [140], it has been estimated that from 40 to 100% of patients allergic to 
cow milk proteins can tolerate goat milk intake [141]. However, clinical and 
immunochemical studies aimed at evaluating goat milk safety for cow milk allergic subjects 
have demonstrated that goat milk cannot be a substitute for cow milk without risk of 
anaphylactic reactions [142,143]. It has been suggested that evidence for goat milk tolerance 
in clinical trials can be due, at least in part, to a higher number of genetic polymorphisms in 
goat CNs, especially for αs1-CN [144]. Null or reduced expression of αs1-CN in individual 
goats; consequently, the overall αs1-CN content in goat bulk milk is lower than that found in 
cow bulk milk. According to this general finding, and taking into account that little β-Lg 
persists in cheese, fresh cheese produced from raw milk has been suggested to be a 
promising hypoallergenic protein source [145]. Unexpectedly, water buffalo milk yogurt has 
successfully been employed as an alternative food for children with cow milk allergies [146] 
despite homologous proteins from cow and water buffalo milk [147]. In contrast, several 
studies have reported the existence of allergies to goat and sheep milk [148-151] and cheese 
[152,153] in patients with tolerance to cow milk proteins. Overall, this type of allergy is less 
common and occurs later than that initiated by cow milk proteins, which is likely because 
goat and sheep dairy products are not usually included in an infant diet. Moreover, IgE 
epitopes have been widely recognized in the CN components of goat and sheep milk. 
Differences in the degree of CN phosphorylation, on average lower in goat and sheep milk 
than in cow milk, rather than differences in IgE epitope sequences, may be involved in 
initiating selective allergies to goat and sheep milk, as observed in recent cases. In addition 
to the four ruminant species of dairy interest (i.e., cow, water buffalo, sheep and goat), other 
monogastric mammals produce milk for human consumption, such as mares and donkeys. 
Mare milk, which is more similar to human than cow milk, has been proven to be an 
acceptable substitute of cow milk for children with severe IgE-mediated cow milk allergy; 
although the evidence of its tolerability by a supervised oral challenge test is recommended 
[154]. However, mare milk availability is limited, and its collection is difficult. Donkey milk 
provides nutritional adequacy and excellent palatability similar to that of mare milk but is 
more readily available. The composition of donkey milk is more similar to human milk than 
cow milk because of the higher lactose content (6.5 vs. 5 g/100 mL), lower protein content 
(1.2 vs. 3.2 g/100 mL), lower CN/whey protein ratio (approximately 1 vs. 4) and a higher 
non-protein nitrogen fraction level (0.29 vs. 0.18%) [155]. These features have prompted 
clinicians to propose donkey milk as a valuable breast milk substitute. Additionally, donkey 
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milk intake has demonstrated positive effects in the diet therapy of patients allergic to cow 
milk proteins [156]. Although the mechanism of this tolerance is unclear, the reduced 
allergenic properties of donkey milk can be related to the structural differences compared 
with bovine milk. Because of scientific and clinical interest in donkey milk, characterization 
of the whey protein fraction [157], caseome [158], and the minor protein components [159] of 
donkey milk have been recently provided. Presently, milk from mammals with a 
geographically restricted distribution area, such as reindeer living in Northern Europe, has 
been utilized to overcome immunological cross-reactivity among proteins from mammals 
other than cows. In particular, β-Lg from reindeer milk, although belonging to the lipocalin 
family and similar to its homologous bovine protein, lacks several IgE epitopes of bovine β-
Lg that are involved in CMA [160]. Recently, camel milk, mainly available in the Gulf area 
and Mauritania, is of growing interest to both nutritionists and pediatricians because of its 
high nutritive value and unique electrophoretic protein patterns, which strongly suggest a 
different immunological reactivity of camel milk proteins with respect to the bovine 
counterparts [161]. 
6.2. Gut microflora 
It has been suggested that gut flora may be involved in the etiology of atopic diseases. It has 
been demonstrated that the gut microflora differs in children with high or low rates of 
allergy. Commensal gut flora play a role in inducing an oral tolerance, and the importance 
of the intestinal microbiota in developing food allergies is essential at early ages when the 
mucosal barrier and immune system are still immature. Probiotics interact with the mucosal 
immune system by the same pathways as commensal bacteria. A recent study has 
demonstrated that probiotic bacteria induced in vivo increased plasma levels of IL-10 and 
total IgA in children with allergic predisposition. Many clinical studies have reported 
significant benefits by probiotics supplementation in FA prevention and management. 
However, not everyone agrees on the effectiveness of probiotics supplementation. The 
differences are most likely related to the selected populations and probiotic strains used. 
The hygiene hypothesis proposes that disturbances in the gastrointestinal microbiota are 
associated with increased prevalence of allergic and autoimmune diseases [162]. Changes in 
the establishment of gut microbiota have been observed in Western infants [163,164]. This is 
most likely because of improved hygiene and cleanliness in Western countries and excessive 
use of antibiotics, which causes a reduced bacterial stimulus. Several clinical studies have 
reported differences in the composition of bacterial communities in the feces of children 
with and without allergic diseases. Many of those studies have highlighted the involvement 
of Bifidobacterium and Bacteroides in the protection against the development of atopy [165-
168], but this observation remains a matter of debate [162]. Moreover, the mechanisms 
underlying such protective effects remain elusive. There is increasing evidence that T-
regulatory cells derived from the thymus or induced in the periphery including the gut 
mucosa [169,170] are key players of immune regulation [171-173]. Using a single strain 
mouse model and defined bacterial communities and conventional mice, it has been recently 
demonstrated that the gut microbiota plays a protective role against allergen sensitization 
and allergic response in a mouse model of FA [174]. The difference between healthy and 
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allergic children may be in their microflora. At 3 weeks of age, infants in whom atopy 
developed then had more Clostridia and fewer bifidobacteria in their feces compared with 
infants who remained healthy. Moreover, fecal bifidobacteria microflorae were different 
between healthy and allergic children; the healthy infants' microflora was mainly 
Bifidobacterium bifidum, whereas the microflora was mainly Bifidobacteria adolescentis in the 
allergic infants. It can be hypothesized that individual species, rather than an entire genus, 
can affect the manifestation of allergy. In a recent study, the microflorae of milk-
hypersensitive and control adults before and after a 4-week supplementation with probiotic 
bacteria (Lactobacillus rhamnosus GG, ATCC 53103) have been studied. The anaerobic 
microflora before supplementation was comparable between the healthy and hypersensitive 
subjects, whereas the response after supplementation was different. The number of 
bifidobacteria in the healthy subjects increased significantly after supplementation. However, 
this did not occur with the supplementation in milk-hypersensitive subjects; this may be 
because of altered intestinal integrity. However, other studies have suggested a beneficial 
effect of probiotic bacteria in milk-hypersensitive subjects. In one study, symptoms of 
hypersensitivity abated along with an elimination diet in 28% of the patients in 4 years. It 
can be hypothesized that with milk elimination and long-lasting probiotic treatment, the 
intestinal severity of IgE-mediated hypersensitivity reactions may increase the intestinal 
microflora or even eliminate them.  
6.3. Reduction of allergenicity of milk proteins by hydrolysis 
The main objective of the milk industry is to supply products while preserving both the 
nutritive value and safety against developing allergies. Nutritional value is preserved by 
exposing liquid or powdered milk to low heat treatments to reduce heat susceptible amino 
acid side chain modifications and preserve the integrity of triacylglycerols, native vitamins 
and other milk components. As noted above, infants can develop milk allergies because of 
increased gut permeability to large molecules, in addition to other causes [175]. This result is 
supported by measurements of unmodified proteins or partially modified proteins in the 
sera of infants and adults [176]. Milk proteins have a molecular mass between 14 and 80 
kDa. To reduce allergenicity, milk proteins can be submitted to different hydrolysis 
procedures. Attempts to classify products by protein hydrolysis include “extensive” or 
“high degree” hydrolysis and “partial” or “low degree” hydrolysis. The rationale of such a 
classification is the spectrum of peptide molecular weights or the ratio of α amino acids to 
total nitrogen. For quality assurance, in vitro product characterization requires size 
measurements of the peptides that are generated by protein hydrolysis and then an in vivo 
allergenicity determination. The in vivo step would include evaluating immunogenic or 
allergenic effects in a recipient infant. The European Union regulates that infant formulas 
contain immunoreactive proteins in quantities lower than 1% of nitrogen compounds [177] 
to reduce allergenicity knowing that only pure amino acids are strictly non-allergenic. This 
criterion could be encountered by milk proteins that have undergone extensive hydrolysis 
partially to cleave amino acids [178-180]. In contrast, formulas with moderately reduced 
allergenicity (partially hydrolyzed) are not recommended for the treatment of allergies 
because of the high amounts of residual allergens [181]. The low quantity of native proteins  
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or residual high molecular mass peptides may produce adverse effects in highly sensitive 
patients. Therefore, a milk hydrolysate can be considered safe and non-allergenic if the 
nitrogen fraction does not contain unmodified milk proteins or high molecular mass 
peptides [178-180]. In the latter case, the product could be classified in the “low degree” 
protein hydrolysate category. However, the antigenic properties of protein hydrolysates 
may not be dependent on the molecular size of the peptide components alone [182]. By 
comparing protein structures with known allergens and allergen epitopes, protein 
allergenicity has been predicted [183]. Although this is true for crystallized proteins, such as 
α-La, β-Lg and Lf, this procedure cannot be applied to uncrystallized CNs. Because infants 
who are diagnosed for milk protein allergies must ingest foods that exclude the causal 
protein, including those ingested by the mother and filtered in breast milk, extensively 
hydrolyzed milk formulas are used for the development of appropriate dietary and 
management strategies. Preclinical testing of infant formulas is necessary to characterize the 
molecular properties and residual antigenicity of proteins [184-186]. Stringent criteria 
specify that extensively hydrolyzed CN with a molecular weight below 5000 Da should be 
reduced by at least 99.99%. There is a need for accurate diagnostic methods to confirm the 
amount of extensively hydrolyzed CN. Milk for allergic infants would consist of extensively 
hydrolyzed CN and whey proteins of which at least 99.99% of the hydrolysis products have 
molecular weights below 5000 Da. The crucial criterion is for the level of allergens to be 
sufficiently low as to cause no significant reaction, even in infants who are highly allergic to 
cow's milk. There have been no reports of adverse reactions because of whey [187, 188] and 
CN hydrolysates [189-191]. Therefore, caution must be maintained that milk formulas 
destined to infants with milk allergies contain correctly hydrolyzed proteins. This generic 
indication requires that molecular properties and residual antigenicity of proteins would be 
characterized [184-186]. In vitro incubation of milk proteins with pepsin, trypsin, and 
chymotrypsin causes the cleavage of numerous peptides of various sizes. Bacterial, fungal 
and plant proteases may also act as hydrolyzing agents. Various enzyme combinations, such 
as alcalase, pancreatin and enzymes from fungal sources, have been utilized to produce 
protein hydrolysates. Commercial hypoallergenic products are currently characterized by 
an average degree of hydrolysis (DH) of the protein components. The DH 19 milk protein 
value is calculated from the increase of the number of primary amino groups compared to 
that of native proteins. In practice, the DH value could vary from 1 to 100% in the case of 
total hydrolysis of the proteins. In the case of partly hydrolyzed proteins, intact and partly 
hydrolyzed proteins are visible bands along an electrophoretic pattern of the products. Two 
commercial formula preparations with DH values of 6.3 and 1.3% contained some intact β-
Lg and peptides with an Mr between 6000 and 8000 Da [192]. Using gel permeation 
chromatography, quantitative results on peptides with an Mr larger than 10 kDa were 
obtained [192]. Regardless of the technique used, descriptive information was obtained on 
either the molecular mass or the origin of the peptides. As a result, consumption of infant 
formulas by allergic patients cannot be attributed to one specific protein or high molecular 
mass peptide. To suppress or reduce the antigenicity of peptides, natural enzyme cleaving  
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of many or most of the peptide bonds is required. In this manner, epitopes that determine 
the antigenicity of the protein molecules are destroyed. This result proves that evaluation of 
the adequacy of infant formula composition in preventing or delaying antigenicity is not 
based solely on DH or Mr determination. In highly sensitized infants with IgE-mediated 
cow's milk allergies, life-threatening anaphylactic shock usually develops shortly after the 
consumption of claimed hypoallergenic milk products in which a number of epitopes would 
have survived in the highly proteolytic environment. The possibility of using well-
characterized monoclonal antibodies in ELISA tests can be used for assessing the origin of 
immunoreactive bovine milk proteins. Because the clinical significance of residual 
antigenicity requires prior molecular approaches, hypoallergenic products may first be 
screened for peptide identification in hydrolyzed milk products. Although protein 
hydrolysates can provide a positive effect, they can contain undefined peptide 
components, which are undesirable for pharmaceutical production purposes. In many 
cases, hydrolysates are produced by methods that are not well-controlled. Other 
complications arise from the raw starting material and differences in processing that lead 
to lot-to-lot hydrolysate composition variability. For these reasons, constant chemically 
defined products are needed. The data presented here represent the initial steps that have 
been taken to identify peptides treated with pepsin (P) and trypsin (T) and were used in 
succession to hydrolyze commercial milk protein powder (PT hydrolysate). To mimic 
commercial milk hydrolysates, the protein powder was treated with enzymes after a 
thermal shock deactivation treatment. Subsequently, the peptides are identified. RP-
HPLC fractionation was used to aid with the peptide separation. In Figure 5, the 
hydrolysate was analyzed to demonstrate a correlation between proteolytic enzymes and 
the presence of peptides. Commercial milk protein hydrolysates may contain trace 
amounts of allergenic proteins whose molecular weights were determined by MALDI-
TOF analysis. Among the number of peptides present in the hydrolyzed sample, the 
proteins/peptides exhibited molecular masses less than or equal to 2431 Da (Figure 6). 
This means that the CNs and whey proteins were digested by pepsin and trypsin into 
peptides with masses less than 3000 Da. This type of hydrolysate is not expected to elicit 
allergic reactions in already sensitized allergic patients (neither anaphylactic shock nor 
positive passive cutaneous anaphylaxis), as verified in experimental animals [193]. LC-
ESI-MS/MS analysis was performed on the hydrolysate to identify peptides occurring 
herein. No sequence peptides with 3 or 4 residues were detected because the MALDI 
signals were acquired at a mass gate of m/z 400. Because some short peptides were in the 
hydrolysate, milk proteins were hydrolyzed by P and T into oligopeptides with different 
biological activities. In Figure 7, the amino acid sequence of the four bovine CN fractions 
and β-Lg are reported with a subscript that indicates the number of amino acid residues 
in MS/MS-identified fragment. 
The proteins in the milk powder sample, which contained modified amino acid residues 
that may indicate the quality of the protein in milk powder, were not examined within the 
present work.  
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Figure 5. MALDI spectra of a sample of milk powder before and after sequential hydrolysis with 
pepsin and trypsin. A search for residual intact proteins and high molecular derived peptides (a) and 
measurements of molecular mass value of oligopeptides in the mixture (b). No peptide at a molecular 
mass higher than 3430.97 Da was observed in the MALDI spectrum. 
 
Figure 6. MALDI analysis of a milk sample after sequential hydrolysis with pepsin and trypsin. A 
molecular mass value corresponds to that of oligopeptides in mixture. No peptide at a molecular mass 
higher than 2207.1 Da was observed in the MALDI spectrum. 
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Figure 7. Primary structure of bovine β-, αs1-, αs2-, κ-CN and β-Lg together with identified peptides in 
commercial milk protein powder sample hydrolysed by sequential action of pepsin and trypsin. 
Protein/enzyme ratio 100/1 (w/w). Incubation with each enzyme was carried out for 16h at appropriate 
pH. Ends of horizontal bars indicate first and last amino acid residue of peptides isolated within this 
work. Arrows indicate casein peptide bonds broken by pepsin (P) and trypsin (T) as reported by 
Pelissier [194].  
7. Oral immunotherapy as future perspective in CMA management 
The primary treatment for managing food allergies is eliminating the offending food from 
the diet. In the case of milk, it is extremely difficult to achieve complete elimination because 
milk can be masked in any number of foods, which may lead to unwanted severe reactions. 
The natural course of a cow’s milk protein allergy is the acquisition of tolerance 
spontaneously through an elimination diet, and 85% of patients overcome CMA by the time 
they are 4-5 years old [195-198]. In recent years, a number of studies have been published 
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regarding desensitization or oral tolerance to food antigens, particularly to cow’s milk. 
Major advances in understanding the immunological processes involved in the 
development of CMA have revealed a considerable number of allergenic epitopes and the 
heterogeneity of allergic responses. Importantly, an elimination diet of dairy foods has 
negative consequences in terms of inadequate calcium and vitamin intake. In the literature, 
several conflicting studies have reported on possible desensitizing therapies in the treatment 
of FA allergies. The possibility to obtain an oral desensitization is now gaining acceptance 
widely, even if the mechanism is still unclear. Oral tolerance or desensitization is the active 
non-response of the immune system to an antigen through sublingual, oral administration. 
Tolerance or the long-term loss of allergic reactivity follows a desensitization treatment. In 
the literature, several studies have reported on possible physiopathogenetic mechanisms of 
oral desensitization, but the exact mechanism is still unknown. That tolerance may be involved 
in the mechanism of desensitization is still uncertain [199-201]. A growing understanding of 
the molecular and cellular mechanisms of oral tolerance is reinforcing advances in potential 
therapies for food allergies and is pivotal to eventually curing allergies in sensitized 
individuals. Oral desensitization should be taken into consideration in the management of 
food-allergic patients even if the physiopathogenetic mechanisms are still unexplained. 
Moreover, this treatment should be considered, particularly for children, because elimination 
from the diet of some foods (e.g., milk and eggs) for these patients could cause psychological 
and/or nutritional problems. Oral immunotherapy (oral desensitization) may be a promising 
treatment strategy for cow’s milk allergy in children and valuable for other foods, such as eggs 
or peanuts. Although the mechanisms of IgE-mediated allergies are fairly well understood, the 
immunology and variety of non-IgE-mediated reactions remains largely unknown. A better 
understanding of these allergy mechanisms is a prerequisite to the development of improved 
diagnostics, which in turn will facilitate an improved understanding of the epidemiology of 
CMA, particularly for non-IgE-mediated reactions. 
8. Conclusions 
A better understanding will also aid the development of hypoallergenic dairy products, 
especially for adults with CMA for whom there is currently a dearth of suitable low-
allergenic dairy products. Some of the risk factors for developing CMA have been identified; 
a familiar history of atopy is one of the main determinants. However, the mechanisms of 
allergic sensitization and the precise interactions between genetics and various 
environmental factors that lead to CMA remain unclear. The first few months of life, during 
which the immune system is still maturing, appear to be a critical risk period for allergic 
sensitization. For at-risk infants with at least one atopic parent, breastfeeding during this 
period is currently the best identified preventative strategy; the use of hydrolyzed formulas 
is recommended for babies who cannot be breastfed. The use of immunomodulatory dietary 
adjuvants, such as probiotics, is an emerging approach with considerable promise for 
primary prevention. For CMA sufferers, the avoidance of dietary milk proteins remains the 
only effective management strategy but carries with it nutritional implications, particularly 
for adequate vitamin and calcium intake as well as protein and energy where unorthodox 
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alternative diets are implemented. Increasing knowledge of the molecular and cellular 
mechanisms of oral tolerance reinforces the advances in potential FA therapies and is 
pivotal to eventually curing allergies in sensitized individuals. Unraveling the links between 
innate and adaptive immunity and characterizing the roles of dendritic cells and T cells in 
directing immune responses and homeostasis to environmental antigens are likely to remain 
a focus of fundamental FA research in the coming years. 
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